Paper · 35022204
Hallmarks of Cancer: New Dimensions.
Hanahan D. Cancer Discov, 2022. Cited by 7,701 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Hallmarks of Cancer: New Dimensions. Papers, record 35022204. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35022204
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Epigenomics | Major topic |
| Neoplasms | Major topic |
| Tumor Microenvironment | Major topic |
| Humans |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07007169 | Mediterranean Diet and Inequality in Early Breast Cancer | Background |
Source ClinicalTrials.gov
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by6,010
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7,701 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,985,469 | Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes. | Oncol Res | 2026 | https://conductscience.org/library/papers/42985469 | PubMed |
| 42,985,391 | Integrative Multi-Omics and Single-Cell Analyses Identify FKBP10 as a CAF-Associated Biomarker Linked to ECM Remodeling and Aggressiveness in Neuroblastoma. | Oncol Res | 2026 | https://conductscience.org/library/papers/42985391 | PubMed |
| 42,984,859 | Origin of cancer: what is a (cancer) cell? A systems-complexity perspective - principles of cellular systems [part 1]. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42984859 | PubMed |
| 42,984,716 | Hijacking of neural circuits by malignant glioma: mechanistic insights and clinical implications. | J Natl Cancer Cent | 2026 | https://conductscience.org/library/papers/42984716 | PubMed |
| 42,984,529 | Editorial: Mechanisms of drug resistance in cancer: overcoming barriers with novel pharmacological strategies. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42984529 | PubMed |
| 42,983,353 | Pretreatment serum IRAK4 and NLRP3 concentrations, their combined score, and overall survival in non-small cell lung cancer: a retrospective single-center cohort study. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42983353 | PubMed |
| 42,980,886 | IAP proteins and ferroptosis in breast cancer: an evidence framework for the ILP-2 hypothesis. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42980886 | PubMed |
| 42,980,830 | Immunohistochemical analysis of toll-like receptors 3 and 9 in relation to apoptosis and tumor growth in a prostate cancer xenograft model. | Histochem Cell Biol | 2026 | https://conductscience.org/library/papers/42980830 | PubMed |
| 42,979,076 | NLRP3 signalling in NSCLC: distinguishing expression, inflammasome activation and context-dependent function. | Front Immunol | 2026 | https://conductscience.org/library/papers/42979076 | PubMed |
| 42,979,040 | Naringenin in pancreatic cancer: emerging evidence on the tumor immune-stromal microenvironment, immunometabolic reprogramming, microbiota-host crosstalk, and therapeutic resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42979040 | PubMed |
1 to 10 of 6,010
See all 6,010 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35022204
GET https://conductscience.org/api/papers/v1/35022204/cited_by?page=2